Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil.
CD38 expression by B-cell chronic lymphocytic leukemia (B-CLL) cells has been the focus of several recent studies. The aim of this study was to evaluate the prognostic impact of CD38 expression by peripheral blood lymphocytes on progression-free survival after first-line therapy with high-dose chlorambucil in 53 previously untreated patients affected by typical CD5+ CD23+ B-CLL.
Morabito
Fortunato
F
Mangiola
Massimo
M
Stelitano
Caterina
C
Deaglio
Silvia
S
Callea
Vincenzo
V
Malavasi
Fabio
F
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000328:Adult; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000737:chemistry*; D002699:Chlorambucil / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D015993:Life Tables; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D009244:NAD+ Nucleosidase / Q000032:analysis*; D014411:Neoplastic Stem Cells / Q000737:chemistry*; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018906:Antineoplastic Agents, Alkylating; D008562:Membrane Glycoproteins; D002699:Chlorambucil; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1